XML 43 R33.htm IDEA: XBRL DOCUMENT
v3.25.2

Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended |
--- | --- | --- | ---
Jun. 29, 2025 | Jun. 30, 2024 | Jun. 29, 2025 | Jun. 30, 2024 | Dec. 29, 2024
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | $ 720,284 | $ 691,685 | $ 1,385,046 | $ 1,341,605 |
Unbilled Receivables | 91,100 |  | 91,100 |  | $ 80,600
Deferred Revenue | 225,300 |  | 225,300 |  | 212,800
Customer Deposits in Advance of Transfer of Control, Current | $ 19,000 |  | $ 19,000 |  | $ 19,500
Remaining Performance Obligations |  |  | Transaction price allocated to the remaining performance obligationsThe Company applies the practical expedient and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company. The remaining performance obligations primarily include noncancelable purchase orders, noncancelable software subscriptions and cloud service contracts and long-term prepaid storage contracts. |  |
Contract with Customer, Asset and Liability [Abstract] |  |  |  |  |
Contract with Customer, Asset, Net, Current - Not Material | The Company had no material contract assets as of June 29, 2025 and December 29, 2024. |  |  |  |
Americas [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | $ 323,580 | 307,783 | $ 628,209 | 602,137 |
Europe [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | 203,632 | 184,588 | 385,424 | 363,150 |
Asia [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | 193,072 | 199,314 | 371,413 | 376,318 |
Diagnostics [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | 354,386 | 343,160 | 678,753 | 656,566 |
Diagnostics [Member] | Americas [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | 126,509 | 117,993 | 246,859 | 235,770 |
Diagnostics [Member] | Europe [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | 119,334 | 110,036 | 225,104 | 211,142 |
Diagnostics [Member] | Asia [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | 108,543 | 115,131 | 206,790 | 209,654 |
Life Sciences [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | 365,898 | 348,525 | 706,293 | 685,039 |
Life Sciences [Member] | Americas [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | 197,071 | 189,790 | 381,350 | 366,367 |
Life Sciences [Member] | Europe [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | 84,298 | 74,552 | 160,320 | 152,008 |
Life Sciences [Member] | Asia [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | 84,529 | 84,183 | 164,623 | 166,664 |
Life Sciences Solutions [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | 298,052 | 297,782 | 584,505 | 589,394 |
Life Sciences Solutions [Member] | Diagnostics [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | 0 | 0 | 0 | 0 |
Life Sciences Solutions [Member] | Life Sciences [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | 298,052 | 297,782 | 584,505 | 589,394 |
Software [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | 67,846 | 50,743 | 121,788 | 95,645 |
Software [Member] | Diagnostics [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | 0 | 0 | 0 | 0 |
Software [Member] | Life Sciences [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | 67,846 | 50,743 | 121,788 | 95,645 |
Reproductive health [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | 135,568 | 129,908 | 262,373 | 254,653 |
Reproductive health [Member] | Diagnostics [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | 135,568 | 129,908 | 262,373 | 254,653 |
Reproductive health [Member] | Life Sciences [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | 0 | 0 | 0 | 0 |
Applied genomics [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue |  | 691,685 |  | 1,341,605 |
Immunodiagnostics [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | 218,818 | 213,252 | 416,380 | 401,913 |
Immunodiagnostics [Member] | Diagnostics [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | 218,818 | 213,252 | 416,380 | 401,913 |
Immunodiagnostics [Member] | Life Sciences [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Segment revenue | $ 0 | $ 0 | $ 0 | $ 0 |

X
- Definition Contract with Customer, Asset, Net, Current - Not Material + References No definition available. + Details
Name: | revv_ContractWithCustomerAssetNetCurrentNotMaterial
Namespace Prefix: | revv_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Customer Deposits Received in Advance of Transfer of Control, Current + References No definition available. + Details
Name: | revv_CustomerDepositsInAdvanceOfTransferOfControlCurrent
Namespace Prefix: | revv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Remaining Performance Obligations + References No definition available. + Details
Name: | revv_RemainingPerformanceObligations
Namespace Prefix: | revv_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Unbilled Receivables + References No definition available. + Details
Name: | revv_UnbilledReceivables
Namespace Prefix: | revv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=srt_AmericasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_AsiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=revv_DiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=revv_LifeSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | revv_MajorGoodsserviceLinesAxis=revv_LifeSciencesSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | revv_MajorGoodsserviceLinesAxis=revv_SoftwareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | revv_MajorGoodsserviceLinesAxis=revv_ReproductiveHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | revv_MajorGoodsserviceLinesAxis=revv_AppliedGenomicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | revv_MajorGoodsserviceLinesAxis=revv_ImmunodiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |